Precise immune tolerance for hPSC derivatives in clinical application.

Area of Science:

• Regenerative Medicine
• Immunology
• Biotechnology

Background:

• Human pluripotent stem cells (hPSCs) can differentiate into various somatic cells, holding promise for regenerative medicine.
• The clinical application of hPSC derivatives is hindered by immunogenicity and immune tolerance induction challenges, potentially increasing tumorigenesis risks.
• Advances in transplantation immunology and genetic engineering offer new strategies to overcome these barriers.

Purpose of the Study:

• To review current understanding of hPSC immunogenicity.
• To explore strategies for inducing immune tolerance in hPSC derivatives for transplantation.
• To highlight the potential of genome editing technologies in this field.

Main Methods:

• Literature review of immunogenicity and immune tolerance induction strategies for hPSC derivatives.
• Focus on graft cell modification approaches.
• Exploration of genome editing technologies like CRISPR-Cas9.

Main Results:

• Significant progress has been made in understanding hPSC immunogenicity.
• Various strategies, including cell modification and genetic engineering, are being explored to induce immune tolerance.
• Genome editing offers precise control over immune responses for allogeneic transplantation.

Conclusions:

• Overcoming immunogenicity is crucial for the clinical translation of hPSC therapies.
• Genetic engineering and genome editing hold significant potential to create immune-evasive hPSC derivatives.
• These advancements could lead to hPSC-based therapies acting as 'wide spectrum drugs'.